The novel RNA polymerase I transcription inhibitor PMR-116 exploits a critical therapeutic vulnerability in a broad-spectrum of high MYC malignancies.
Rita Ferreira, Katherine M. Hannan, Kostya I. Panov, Thejaani P. Udumanne, Amee J. George, Adrià Closa, Zaka Wing-Sze Yuen, Eduardo Eyras, Perlita Poh, Kylee H. Maclachlan, Mitchell Dwyer, Vanessa Barn, Jin-Shu He, Eric P. Kusnadi, Richard J. Rebello, , Nadine Hein
This study shows PMR-116, a second-generation RiBi inhibitor, effectively targets high-MYC cancers without causing DNA damage, suggesting RiBi as a viable cancer therapy.
bioRxiv · Apr 19, 2025 · PreprintCancer Biology